PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Cyclr is a cloud-based software that allows the user to connect the apps that they already run their business on. This makes it simple to synchronise data with another system.
days to go:
Expired
investment:
£100,490
Zvilo aims to become a major challenger bank in the Balkans for Balkan people living in the European Economic Area (EEA). It plans to disrupt the outdated Balkan banking sector and become a contender in an estimated remittances per annum market worth €14 billion. The company asserts that it has procured a letter of intent for a pilot program that would allow it to offer business lending to 800+ Small and Medium Enterprises (SMEs) and financial services to 45,000+ potential personal banking customers. It has also initiated a licensing application with the Central Bank of Kosovo and partnered with Mastercard as its card partner. Zvilo will use the investment to formalise its application for Supply Chain Finance (SCF) licensing in Kosovo, execute its strategic partnership agreement with its Kosovar partner retailer, prepare for a second fundraising round, and expand its services.
days to go:
Expired
investment:
£666,085
MergerLinks is a platform where global dealmakers can connect and identify with transaction counterparts based on their relationships and credentials. The company collates proprietary and public transactions data and assembles it into an information tool. MergerLinks also forms an ecosystem where clients can easily access advisory services. This is done by contacting and identifying people with the right skill set and network. Most of the revenue generated by MergerLinks comes from the sale of B2B subscriptions to a range of connectivity and data tools. With the proceeds, the company will market its premium subscriptions, build the network of content distribution partners, and build Customer Success function.
days to go:
Expired
investment:
£239,270
Easily understand and manage all your insurance in one simple app, ready for the digital age. Wrisk is all about transparency and allows customers to see how much they’re currently paying for their insurance, what actions they can take to reduce their risk and purchase the insurance seamlessly from within the app. Wrisk is seeking investment to expand and cater for as many insurance needs as possible.
days to go:
Expired
investment:
£1,044,630
Enoron is a management system that allows lawyers to easily manage all their clients and all their related information, all their matters and deadlines, keeping track of all their activities, timesheets and accounting and much more.
days to go:
Expired
investment:
£31,896
A multi-award winning investment platform providing customers with ISA eligible loans. Crowdstacker are fully FCA regulated and set a record for the largest crowdfunded P2P loan in the UK, valued at £15m. With the recent release of Innovative Finance ISA, the company is expecting to see rapid growth in the near future.
days to go:
Expired
investment:
£818,210
